BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
(NASDAQ:BBIO) PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (âBridgeBioâ or the âCompanyâ), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025.
Related Questions
How will the upcoming Phase 2 proofâofâconcept data for Encaleret affect BBIO's shortâterm stock volatility?
What is the total addressable market and commercial upside for an oral therapy in postâsurgical hypoparathyroidism versus existing treatments?
How does BridgeBio's development timeline and data expectations compare with competitors developing therapies for hypoparathyroidism or related skeletal dysplasias?